
New Phase 3 study shows TALVEY plus daratumumab boosts survival in relapsed multiple myeloma patients.
Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to...



